{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-193412","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.610369+00:00","generated_at":"2026-05-31T13:12:14.690720+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nuvation Bio Q2 net loss $462.5M on $425.1M AnHeart charge; halts NUV-868 Phase 2","bullets":["Net loss of $462.5M ($1.89/share) vs. $20.6M ($0.09) Q2 2023; includes $425.1M acquired IPR&D charge from AnHeart acquisition.","Cash, equivalents, and marketable securities of $577.2M as of June 30, 2024.","R&D expenses $29.2M (up 57% YoY) and G&A $16.1M (up 115% YoY) partly due to AnHeart.","Decided not to initiate Phase 2 for NUV-868 in prior solid tumor indications; evaluating next steps.","Taletrectinib NDA planned in U.S. in 2025 based on pooled TRUST-I/II data at ESMO 2024; received FDA Orphan Drug Designation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-193412","json":"https://secwatch.observer/filing/0001193125-24-193412.json","markdown":"https://secwatch.observer/filing/0001193125-24-193412.md","text":"https://secwatch.observer/filing/0001193125-24-193412.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524193412/0001193125-24-193412-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524193412/d867853d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:12:14.690720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}